{"filing":{"accession_number":"0001140361-26-036563","cik":"0001281895","ticker":"RCKTW","company_name":"ROCKET PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-09-15","report_date":"2026-09-15","primary_document":"ef20082010_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1281895/000114036126036563/ef20082010_8k.htm"},"events":[{"id":33459,"run_id":30765,"accession_number":"0001140361-26-036563","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This disclosure announces FDA alignment on key clinical trial parameters for RP-A501 in Danon disease, including confirmation of a 12-patient pivotal population, recalibrated dose, and 12-month co-primary endpoints intended to support accelerated approval. While this is a material regulatory and clinical milestone affecting the company's development pathway, it does not fit neatly into the specific event categories (not a restatement, impairment, covenant breach, or other defined financial/legal/governance event). The event is clearly operational—a significant clinical development milestone—making operational_other the most appropriate classification.","company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKTW","filing_date":"2026-09-15","form":"8-K","submitted_at":null,"items":[{"id":36910,"accession_number":"0001140361-26-036563","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This disclosure announces FDA alignment on key clinical trial parameters for RP-A501 in Danon disease, including confirmation of a 12-patient pivotal population, recalibrated dose, and 12-month co-primary endpoints intended to support accelerated approval. While this is a material regulatory and clinical milestone affecting the company's development pathway, it does not fit neatly into the specific event categories (not a restatement, impairment, covenant breach, or other defined financial/legal/governance event). The event is clearly operational—a significant clinical development milestone—making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T11:07:53.167743+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36910,"accession_number":"0001140361-26-036563","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This disclosure announces FDA alignment on key clinical trial parameters for RP-A501 in Danon disease, including confirmation of a 12-patient pivotal population, recalibrated dose, and 12-month co-primary endpoints intended to support accelerated approval. While this is a material regulatory and clinical milestone affecting the company's development pathway, it does not fit neatly into the specific event categories (not a restatement, impairment, covenant breach, or other defined financial/legal/governance event). The event is clearly operational—a significant clinical development milestone—making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T11:07:53.167743+00:00","company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKTW","filing_date":"2026-09-15"}]}